Targeted Drug Delivery System Market

Targeted Drug Delivery System Market for Biologics by Device Type, Target Organ, Therapeutic Area, Target Indication and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Companies Covered
    276

  • Pages
    339

  • View Count
    15526

Targeted Drug Delivery System Market Overview

The targeted drug delivery system market is estimated to be worth $30 million in 2020 and is expected to grow at CAGR of 67% during the forecast period. Over the years, advances in cell biology and pharmacology have led to the development of a variety of advanced biologics, which experts believe, possess the potential to address several unmet needs associated with the treatment of different types of diseases.

Currently, there are more than 1,000 cell and gene therapies under development; most of which are being developed for the treatment of oncological disorders, cardiovascular disorders and neurological disorders. Additionally, over the last decade, multiple immunotherapies have been developed, and have led to a decrease in lung cancer and melanoma-related mortality. Despite their many benefits, biologics present a number of challenges, such as drug delivery related complexities, and immunogenicity concerns, which have been shown to result in systemic toxicity post therapy administration. To avoid such systemic toxic effects, a limited volume of drug is administered, which often results in a small amount of drug reaching the target organ. Further, from a pharmacological point of view, the drug stays at the target site for a limited time, hence decreasing the final therapeutic effect that can be achieved through prolonged and controlled drug delivery. Moreover, some of such treatment options, such as cell therapies, require periodic administration of additional therapy material, or complementary products, thereby, adding to the already complex invasive dosing procedure.   

In order to address some of the abovementioned challenges, a number of innovator companies in the biopharmaceutical sector are actively engaged in identifying targeted and effective delivery strategies for biologics, including gene therapies, cell / stem cell therapies, immunotherapies and therapeutic proteins. Examples of devices designed for the targeted delivery of biologics include (in alphabetic order, no selection criteria) Advance® CS, ExtroducerTM microcatheter, HelixTM biotherapeutic delivery system, ImmunoPulse® IL-12, SmartFlow® neuro ventricular cannula and MailPan®. Some of the aforementioned drug delivery devices have been demonstrated to have an improved therapeutic safety index, and are capable of accurately delivering biological interventions to the target physiological site. Further, certain implantable delivery systems have also been developed in order to prolong the therapeutic effect of biologics. Given the rapid pace of growth within the biopharmaceutical market, the demand for effective delivery systems is anticipated to witness an increase in market growth during the forecast period. This may be expected to create lucrative opportunities for stakeholders in the targeted drug delivery systems market.  

Key Devices in Targeted Drug Delivery System Market

Examples of key devices in targeted drug delivery system market (which have also been profiled in this market report; the complete list of devices and their developer companies is available in the full report) include Alcyone MEMS Cannula, Bullfrog® Micro-Infusion Device, HelixTM Biotherapeutic Delivery System, Orbit Subretinal Delivery System, SmartFlow® Neuro Ventricular Cannula and Renexus®. This market report includes an easily searchable excel database of all the companies providing targeted drug delivery devices, worldwide.

This image highlights the context of Targeted Drug Delivery Devices Market report. In order to address the existing concerns related to the administration of biologics, several innovator companies claim to be developing a range of patient-centric drug delivery devices, intended to improve therapeutic outcomes at relatively lower costs This image provides list of Targeted Drug Delivery Devices for Biologics. Several industry and non-industry players across the world, claim to be involved in the development of a variety of novel medical devices that facilitate the targeted delivery of biologics to different sites in the human body This image presents current market landscape of Targeted Drug Delivery Devices for Biologics. Majority of the devices being developed for targeted delivery of biologics are intended for the delivery of anti-cancer medication, including a number of gene therapies and cell-based interventions

Scope Of the Targeted Drug Delivery System Market Report

The ‘Targeted Drug Delivery System Market for Biologics (Intra-organ / Intra-tumoral), 2020-2030’ market report features an extensive study of the current market landscape, market size, market trends, market share, market forecast, market outlook and future opportunities of the targeted drug delivery system market. The market research report features an in-depth analysis of the key drivers and trends related to targeted drug delivery system market. Amongst other elements, the market research report includes: 

  • A detailed assessment of the companies involved in the development of targeted delivery devices for biologics, providing information and analyses based on a number of relevant parameters, such as type of device (encapsulation based delivery device, catheter, implant, electroporation delivery system, balloon, cannula and microrobot), status of development (approved, clinical and preclinical), target organ (brain, heart, abdomen, breast, eye, and others), target indication (Parkinson's disease, heart failure, diabetes, breast cancer, myocardial infarction, Alzheimer’s, solid tumors (specific type unknown), and others), target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), type of biologic delivered (cells, proteins, antibodies, enzymes, plasmids, growth factors, small peptides, neurotransmitters and modified RNA), type of therapy delivered (gene therapy, stem cell therapy, cell therapy, immunotherapy and RNA therapeutics) and route of administration (intra-tumoral, implantable, intraocular, intraputamen, intra-abdominal, intracardiac and others). In addition, the chapter includes information on the device developers, including details on type of stakeholder (industry and non-industry), year of establishment, company size (only for industry players) and location of headquarters.        
  • Elaborate profiles of devices that are currently approved or being evaluated in later stages of clinical development (phase III and above), featuring an overview of the device, its mechanism of action, current development status and key clinical trial results.
  • An assessment of the research activity in the neurological and cardiovascular disorders domain, in terms of the development of stem cell and gene therapies for the treatment these disorders. The chapter provides information and analysis on the recent publications and grants that are focused on the stem cell and gene therapies being developed for these therapeutic areas.
  • A clinical trial analysis of completed, ongoing and planned studies of various stem cell and gene therapies, based on various parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, type of therapy, therapeutic area, target indication, route of administration, key players, geographical location and enrolled patient population.
  • An analysis presenting the potential strategic partners (primarily stem cell and gene therapy developers) for targeted drug delivery device developers, based on different parameters, such as pipeline strength, target therapeutic area(s) and location of the headquarters of the company. 

The key objective of targeted drug delivery system market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for targeted drug delivery system market during the forecast period. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market, for the forecast period 2020-2030. Our year-wise projections for the current and future opportunity have further been segmented on the basis of [A] type of device (encapsulation based delivery device, catheter, electroporation delivery system, and cannula), [B] target organ (brain, heart, breast, eye, skin and pancreas), [C] target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), [D] target indication (Parkinson's disease, heart failure, breast cancer, melanoma, glioblastoma, myocardial ischemia, geographic atrophy, glaucoma, macular telangectasia, retinitis pigmentosa, non-infectious uveitis and mucopolysaccharidosis type III A) and [E] key geographical regions (North America, Europe and Asia-Pacific). To account for the uncertainties associated with the development of the devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  

This image highlights the promising therapeutic areas for Targeted Drug Delivery Devices. The rising interest of stakeholders in developing stem cell and gene therapies for treating neurological and cardiovascular disorders, can be validated from the growing research and development activity in this domain This image provides list of Stem Cell and Gene Therapy Developers. An assessment of existing stem cell and gene therapy developers revealed that North America is presently a hub for the development of advanced biologics, presenting substantial partnering opportunities for device developers This image provides information on the current and future market trends and potential growth of Targeted Drug Delivery Devices Market for Biologics. The market for drug-device combination products is estimated to be worth over USD 3 billion by 2030; the projected opportunity is likely to be well distributed across key device types, target organs and therapeutic areas

The opinions and insights presented in the market research report were also influenced by discussions held with senior stakeholders in the industry. The market report features detailed transcripts of interviews held with the following industry stakeholders:

  • William L Rust, Founder and Chief Executive Officer, Seraxis
  • Manuel Pires, Junior Business Developer, Defymed
  • R. Lyle Hood, Assistant Professor, University of Texas at San Antonio
  • Anonymous, Postdoctoral Associate, Massachusetts Institute of Technology  

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is targeted drug delivery?

Answer: Targeted drug delivery refers to the administration of pharmaceutical compounds to the designated target organ directly.

Question 2: How big is the targeted drug delivery system market?

Answer: The targeted drug delivery system market size is estimated to be worth $30 million in 2020.

Question 3: What is the projected market growth of the targeted drug delivery system market?

Answer: The targeted drug delivery system market is expected to grow at compounded annual growth rate (CAGR) of 67% during the forecast period 2020 – 2030.

Question 4: What are some leading devices in the targeted drug delivery system market?

Answer: Examples of key devices in targeted drug delivery system market (which have also been profiled in this market report; the complete list of devices and their developer companies is available in the full report) include Alcyone MEMS Cannula, Bullfrog® Micro-Infusion Device, HelixTM Biotherapeutic Delivery System, Orbit Subretinal Delivery System, SmartFlow® Neuro Ventricular Cannula and Renexus®.

Question 5: How much money has been invested by stakeholders in the targeted drug delivery system market?

Answer: In 2019 alone, close to USD 10 billion has been invested by stakeholders in the targeted drug delivery system market, for the development of targeted drug delivery devices.

Question 6: How many companies are currently engaged in the targeted drug delivery system market?

Answer: Close to 40 companies are currently engaged in the targeted drug delivery system market.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com